Synergistic Anti-tumor Effect of ChangTai Keli Based on Chemotherapy for Colon Cancer Patients：a Randomized, Parallel-group, Double-blind, Multicenter Clinical Study

The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients by a randomized, parallel-group, double-blind, multicenter clinical study.

开始日期2015-06-01

申办/合作机构

Nanjing NingQi Medicine Science and Technology Co., Ltd.

[+1]

100 项与 ChangTai Keli 相关的临床结果

登录后查看更多信息

100 项与 ChangTai Keli 相关的转化医学

登录后查看更多信息

100 项与 ChangTai Keli 相关的专利（医药）

登录后查看更多信息

项与 ChangTai Keli 相关的文献（医药）

2021-03-01·Journal of Orthopaedic Translation3区 · 医学

Jingshu Keli for treating cervical spondylotic radiculopathy: The first multicenter, randomized, controlled clinical trial

3区 · 医学

ArticleOA

作者: Shen, Huiyong ; Tong, Peijian ; Qiu, Guixing ; Yang, Zhidong ; Xiao, Weiping ; Zhang, Xueli ; Yang, Huilin ; Zhang, Weibin ; Hu, Jianhua ; Chen, Feng ; Zhu, Tianliang ; Jiang, Hong ; Sun, Tiansheng ; He, Chengjian ; Pan, Yalin ; Chai, Yimin

BACKGROUNDJingshu Keli (or Jingshu granules), a traditional Chinese medicine, are widely used for treating cervical spondylotic radiculopathy in China; however, no randomized, double-blind, controlled study has verified their effectiveness.PURPOSETo evaluate the efficacy and safety of Jingshu Keli for the treatment of cervical spondylotic radiculopathy in a randomized controlled trial.DESIGNFrom August 2015 to July 2017, a multicenter, randomized, double-blind, placebo-controlled trial was conducted at 13 large- and medium-sized hospitals in China.PATIENT SAMPLEA total of 360 and 120 patients were initially enrolled in the Jingshu and control groups, respectively; 386 patients completed the study, with 299 in the Jingshu group and 87 in the control group.OUTCOME MEASURESThe main index for evaluating the curative effect was the pain score on a visual analogue scale (VAS; 0-100 points).METHODSAll patients were administered a bag of Jingshu Keli or placebo 3 times a day for 4 weeks, and were interviewed at the second and fourth weeks. The decrease in pain scores and rate of change in pain scores after treatment were calculated, related laboratory indices were reviewed, and adverse reactions were recorded.RESULTSIn the Per Protocol Set (PPS) analysis, the baseline pain VAS scores in the control and Jingshu groups were 49.31 ± 6.97 and 50.06 ± 7.33, respectively, with no significant difference between the groups (P > 0.05). While there were no differences at 2 weeks between groups, at four weeks the pain VAS scores in the control and Jingshu groups decreased by 12.86 ± 13.45 and 22.72 ± 15.08, respectively relative to the values at baseline, with significant group differences (P < 0.0001). While there were similar significant differences between the groups (P < 0.0001) in the Full Analysis Set (FAS) analyses neither group achieved the minimal clinically important difference at any time point.CONCLUSIONSJingshu Keli are effective for the treatment of cervical spondylotic radiculopathy.TRANSLATIONAL POTENTIAL STATEMENTThis is the first prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial that confirmed the clinical efficacy and safety of Jingshu Keli for treating cervical spondylotic radiculopathy, which can provide evidence for clinical treatment.

2020-02-13·Oxidative Medicine and Cellular Longevity2区 · 生物学

Wenxin Keli Regulates Mitochondrial Oxidative Stress and Homeostasis and Improves Atrial Remodeling in Diabetic Rats

2区 · 生物学

ArticleOA

作者: Zhang, Yue ; Tse, Gary ; Liang, Xue ; Yan, Gan-Xin ; Yuan, Ming ; Zhang, Zhiwei ; Zhao, Yungang ; Yuan, Meng ; Meng, Lei ; Liu, Tong ; Li, Guangping ; Fan, Guanwei ; Gong, Mengqi

Mitochondrial dysfunction and oxidative stress play an important role in the pathogenesis of both atrial fibrillation (AF) and diabetes mellitus (DM). Wenxin Keli (WXKL), an antiarrhythmic traditional Chinese medicine, has been shown to prevent cardiac arrhythmias through modulation of cardiac ion channels. This study tested the hypothesis that WXKL can improve atrial remodeling in diabetic rats by restoring mitochondrial function. Primary atrial fibroblasts of neonatal SD rats were divided into four groups: control, hydrogen peroxide (H2O2), H2O2+WXKL 1 g/L, and H2O2+WXKL 3 g/L groups. Intracellular mitochondrial membrane potential (MMP), reactive oxygen species (ROS), and mitochondrial oxygen consumption were measured. SD male rats were randomly divided into three groups: control, DM, and DM+WXKL groups. Rats in the DM+WXKL group were treated with daily gavage of WXKL at 3 g/kg. After eight weeks, echocardiography, hemodynamic examination, histology, electrophysiology study, mitochondrial respiratory function, and western blots were assessed. H2O2 treatment led to increased ROS and decreased intracellular MMP and mitochondrial oxygen consumption in primary atrial fibroblasts. WXKL improved the above changes. DM rats showed increased atrial fibrosis, greater left atrial diameter, lower atrial conduction velocity, higher conduction heterogeneity, higher AF inducibility, and lower mitochondrial protein expression, and all these abnormal changes except for left atrial diameter were improved in the DM+WXKL group. WXKL improves atrial remodeling by regulating mitochondrial function and homeostasis and reducing mitochondrial ROS in diabetic rats.

2013-06-01·Pacing and Clinical Electrophysiology3区 · 工程技术

Wenxin Keli Suppresses Ventricular Triggered Arrhythmias via Selective Inhibition of Late Sodium Current

3区 · 工程技术

Article

作者: B S Tengxian Liu ; Jiana Li ; Donglin Guo M.D. ; Juan Shu M.D. ; Gan-Xin Yan M.D. ; Hongmei Sun ; Dan Wang ; Xiaolin Xue ; Lin Yang

BackgroundWenxin Keli is a popular Chinese herb extract that approximately five million Asians are currently taking for the treatment of a variety of ventricular arrhythmias. However, its electrophysiological mechanisms remain poorly understood.Methods and resultsThe concentration‐dependent electrophysiological effects of Wenxin Keli were evaluated in the isolated rabbit left ventricular myocytes and wedge preparation. Wenxin Keli selectively inhibited late sodium current (INa) with an IC50 of 3.8 ± 0.4 mg/mL, which was significantly lower than the IC50 of 10.6 ± 0.9 mg/mL (n = 6, P < 0.05) for the fast INa. Wenxin Keli produced a small but statistically significant QT prolongation at 0.3 mg/mL, but shortened the QT and Tp–e interval at concentrations ≥1 mg/mL. Wenxin Keli increased QRS duration by 10.1% from 34.8 ± 1.0 ms to 38.3 ± 1.1 ms (n = 6, P < 0.01) at 3 mg/mL at a basic cycle length of 2,000 ms. However, its effect on the QRS duration exhibited weak use‐dependency, that is, QRS remained less changed at increased pacing rates than other classic sodium channel blockers, such as flecainide, quinidine, and lidocaine. On the other hand, Wenxin Keli at 1–3 mg/mL markedly reduced dofetilide‐induced QT and Tp–e prolongation by attenuation of its reverse use‐dependence and abolished dofetilide‐induced early afterdepolarization (EAD) in four of four left ventricular wedge preparations. It also suppressed digoxin‐induced delayed afterdepolarization (DAD) and ventricular tachycardias without changing the positive staircase pattern in contractility at 1–3 mg/mL in a separate experimental series (four of four).ConclusionsWenxin Keli suppressed EADs, DADs, and triggered ventricular arrhythmias via selective inhibition of late INa.

100 项与 ChangTai Keli 相关的药物交易

登录后查看更多信息